IS7749A - Pýrimídínafleiður og notkun þeirra sem CB2 beina - Google Patents

Pýrimídínafleiður og notkun þeirra sem CB2 beina

Info

Publication number: IS7749A
Authority: IS; Iceland
Prior art keywords: direct; pyrimidine derivatives; pyrimidine; derivatives
Prior art date: 2002-08-21

Application number

IS7749A

Other languages

English (en)

Inventor

John Eatherton Andrew

Martin Paul Giblin Gerard

Howard Green Richard (l βtinn)

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-21

Filing date

2005-03-17

Publication date

2005-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-21 Priority claimed from GB0219501A external-priority patent/GB0219501D0/en

2003-04-24 Priority claimed from GB0309326A external-priority patent/GB0309326D0/en

2005-03-17 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2005-03-17 Publication of IS7749A publication Critical patent/IS7749A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IS7749A 2002-08-21 2005-03-17 Pýrimídínafleiður og notkun þeirra sem CB2 beina IS7749A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0219501A GB0219501D0 (en)	2002-08-21	2002-08-21	Compounds
GB0309326A GB0309326D0 (en)	2003-04-24	2003-04-24	Compounds
PCT/EP2003/009217 WO2004018433A1 (en)	2002-08-21	2003-08-19	Pyrimidine derivatives and their use as cb2 modulators

Publications (1)

Publication Number	Publication Date
IS7749A true IS7749A (is)	2005-03-17

Family

ID=31948030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7749A IS7749A (is)	2002-08-21	2005-03-17	Pýrimídínafleiður og notkun þeirra sem CB2 beina

Country Status (34)

Country	Link
US (2)	US7635701B2 (is)
EP (2)	EP1539712B1 (is)
JP (1)	JP4583174B2 (is)
KR (1)	KR20050058367A (is)
CN (1)	CN100351239C (is)
AP (1)	AP2005003219A0 (is)
AR (1)	AR041016A1 (is)
AT (2)	ATE489369T1 (is)
AU (1)	AU2003264076B2 (is)
BR (1)	BR0313676A (is)
CA (1)	CA2495880C (is)
CY (1)	CY1107871T1 (is)
DE (2)	DE60335151D1 (is)
DK (1)	DK1539712T3 (is)
EA (2)	EA012703B1 (is)
EC (1)	ECSP055613A (is)
ES (1)	ES2295682T3 (is)
IL (2)	IL166552A0 (is)
IS (1)	IS7749A (is)
MA (1)	MA27428A1 (is)
MX (1)	MXPA05001960A (is)
MY (1)	MY137053A (is)
NO (1)	NO20051451D0 (is)
NZ (1)	NZ537886A (is)
OA (1)	OA12910A (is)
PE (1)	PE20040898A1 (is)
PL (1)	PL376047A1 (is)
PT (1)	PT1539712E (is)
SI (1)	SI1539712T1 (is)
TW (1)	TW200410946A (is)
UA (1)	UA83194C2 (is)
UY (1)	UY27939A1 (is)
WO (1)	WO2004018433A1 (is)
ZA (1)	ZA200500913B (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY27939A1 (es) *	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
EP1546115A4 (en)	2002-09-27	2010-08-04	Merck Sharp & Dohme	Substituted pyrimidines
TW200505902A (en) *	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands
US20040259887A1 (en) *	2003-06-18	2004-12-23	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
GB0402356D0 (en) *	2004-02-03	2004-03-10	Glaxo Group Ltd	Novel compounds
GB0402355D0 (en) *	2004-02-03	2004-03-10	Glaxo Group Ltd	Novel compounds
NZ588139A (en)	2004-04-08	2012-02-24	Targegen Inc	7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
AU2005276974B2 (en)	2004-08-25	2012-08-02	Targegen, Inc.	Heterocyclic compounds and methods of use
GB0517188D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
KR101467723B1 (ko)	2005-11-01	2014-12-03	탈자진 인코포레이티드	키나제의 비-아릴 메타-피리미딘 억제제
EP1966132A2 (en)	2005-12-15	2008-09-10	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
JP2009536613A (ja) *	2006-04-07	2009-10-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節する化合物
WO2008014199A2 (en)	2006-07-28	2008-01-31	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the cb2 receptor
WO2008032764A1 (en) *	2006-09-13	2008-03-20	Kyowa Hakko Kirin Co., Ltd.	Fused heterocyclic derivative
JP5030114B2 (ja)	2006-09-25	2012-09-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体をモジュレートする化合物
EP2076499B1 (en) *	2006-10-04	2010-05-12	F.Hoffmann-La Roche Ag	Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
US7928103B2 (en)	2006-10-17	2011-04-19	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
CA2695613A1 (en)	2006-12-19	2008-06-26	Pharmos Corporation	Sulfonamide derivatives with therapeutic indications
GB0705803D0 (en) *	2007-03-28	2007-05-02	Glaxo Group Ltd	Novel compounds
KR20100100858A (ko) *	2007-11-06	2010-09-15	에모리 유니버시티	안전한 ｎｍｄａ 수용체 길항제의 식별 방법
WO2009061652A1 (en)	2007-11-07	2009-05-14	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
WO2010005782A1 (en)	2008-07-10	2010-01-14	Boehringer Ingelheim International Gmbh	Sulfone compounds which modulate the cb2 receptor
EP2342199B1 (en)	2008-09-25	2014-02-26	Boehringer Ingelheim International GmbH	Sulfonyl compounds which selectively modulate the CB2 receptor
TW201031649A (en)	2008-12-02	2010-09-01	Organon Nv	1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
TW201031650A (en)	2008-12-02	2010-09-01	Organon Nv	1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
US8524727B2 (en) *	2009-03-30	2013-09-03	Astellas Pharma Inc.	Pyrimidine compound
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
US8383615B2 (en)	2009-06-16	2013-02-26	Boehringer Ingelheim International Gmbh	Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
JP2013505295A (ja)	2009-09-22	2013-02-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を選択的に調節する化合物
WO2011088015A1 (en)	2010-01-15	2011-07-21	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
US8846936B2 (en)	2010-07-22	2014-09-30	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the CB2 receptor
HRP20161111T1 (hr) *	2010-07-29	2016-11-18	Astellas Pharma Inc.	Kondenzirani spojevi piridina kao ligandi cb2 kanabinoidnog receptora
CA2816957A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
WO2014143661A1 (en) *	2013-03-15	2014-09-18	Waterfi, Llc	Method for water-proofing elecronic components
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US10301348B2 (en) *	2013-10-23	2019-05-28	Academia Sinica	Compounds for use in prevention and treatment of neurodegenerative diseases and pain
US10588974B2 (en)	2016-04-22	2020-03-17	Receptor Holdings, Inc.	Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru)	2016-12-02	2019-04-30	Ресептор Лайф Сайенсиз, Инк.	Быстродействующие растительные лекарственные соединения и биологически активные добавки
AR117118A1 (es)	2018-11-19	2021-07-14	Receptor Holdings Inc	Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5518A (en)		1848-04-18		Geaijst-drieb
US4826689A (en)	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr)	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it)	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en)	1990-03-05	1992-05-12	Sterling Drug Inc.	Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
HUT63941A (en) *	1992-05-15	1993-11-29	Hoechst Ag	Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
DK0644755T3 (da)	1992-06-10	1997-09-22	Nanosystems Llc	Overflademodificerede NSAID-nanopartikler
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5346702A (en)	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en)	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en)	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en)	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en)	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en)	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
PL313973A1 (en)	1993-10-12	1996-08-05	Du Pont Merck Pharma	1 n-alkyl-n-arylopyrimidin amines and their derivatives
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5587143A (en)	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en)	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560931A (en)	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en)	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en)	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5534270A (en)	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5622938A (en)	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en)	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
BR9607035A (pt)	1995-02-13	1997-11-04	Searle & Co	Isoxazois substituidos para o tratamento de inflamação
US5573783A (en)	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en)	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
EP0850228A1 (en) *	1995-09-01	1998-07-01	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5811428A (en) *	1995-12-18	1998-09-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk)	1995-10-13	2003-06-16	Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі.	Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
KR100508910B1 (ko)	1995-10-17	2006-04-20	알티피 파마 코포레이션	불용성약물방출
FR2742148B1 (fr)	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
IL125849A (en)	1996-04-12	2003-10-31	Searle & Co	Substituted benzenesulfonamide derivatives, their preparation and pharmaceutical compositions comprising them
IL127441A (en)	1996-07-18	2003-02-12	Merck Frosst Canada Inc	Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
CO4960662A1 (es)	1997-08-28	2000-09-25	Novartis Ag	Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE317845T1 (de)	1997-09-05	2006-03-15	Glaxo Group Ltd	Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
CA2335472C (en)	1998-06-19	2008-10-28	Rtp Pharma Inc.	Processes to generate submicron particles of water-insoluble compounds
JP2002525311A (ja)	1998-10-01	2002-08-13	エランファーマインターナショナル，リミティド	徐放性ナノ粒子組成物
ES2228127T3 (es)	1998-11-03	2005-04-01	Glaxo Group Limited	Derivados de pirazolopiridina como inhibidores selectivos de cox-2.
US6180136B1 (en)	1998-11-10	2001-01-30	Idexx Laboratories, Inc.	Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
JP5296954B2 (ja)	1998-11-20	2013-09-25	オバン・エナジー・リミテッド	不溶性微粒子の安定なサスペンションを製造する方法
US6025683A (en)	1998-12-23	2000-02-15	Stryker Corporation	Motor control circuit for regulating a D.C. motor
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
WO2000052008A1 (en)	1999-02-27	2000-09-08	Glaxo Group Limited	Pyrazolopyridines
GB9927844D0 (en) *	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
PT1175214E (pt)	1999-12-08	2005-04-29	Pharmacia Corp	Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
GB0003224D0 (en) *	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
NZ522783A (en)	2000-06-28	2004-07-30	Smithkline Beecham P	Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
WO2002018380A1 (en)	2000-08-31	2002-03-07	F. Hoffmann-La Roche Ag	7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
EP1363632B1 (en)	2001-01-29	2010-08-25	The University of Connecticut	Receptor selective cannabimimetic aminoalkylindoles
US7507767B2 (en)	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
HUP0303841A2 (hu)	2001-02-20	2004-03-01	Bristol-Myers Squibb Company	2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk
FR2839718B1 (fr)	2002-05-17	2004-06-25	Sanofi Synthelabo	Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2005533809A (ja)	2002-06-19	2005-11-10	シェーリング　コーポレイション	カンナビノイドレセプタアゴニスト
CN1665789A (zh)	2002-06-28	2005-09-07	山之内制药株式会社	二氨基嘧啶酰胺衍生物
EP1534687B1 (en)	2002-08-21	2006-09-27	Glaxo Group Limited	2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators
UY27939A1 (es) *	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
EP1546115A4 (en)	2002-09-27	2010-08-04	Merck Sharp & Dohme	Substituted pyrimidines
GB0222493D0 (en)	2002-09-27	2002-11-06	Glaxo Group Ltd	Compounds
GB0222495D0 (en)	2002-09-27	2002-11-06	Glaxo Group Ltd	Compounds
TW200505902A (en)	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands

2003
- 2003-08-14 UY UY27939A patent/UY27939A1/es not_active Application Discontinuation
- 2003-08-19 MY MYPI20033143A patent/MY137053A/en unknown
- 2003-08-19 WO PCT/EP2003/009217 patent/WO2004018433A1/en not_active Ceased
- 2003-08-19 PL PL03376047A patent/PL376047A1/xx not_active Application Discontinuation
- 2003-08-19 CN CNB038241293A patent/CN100351239C/zh not_active Expired - Fee Related
- 2003-08-19 AP AP2005003219A patent/AP2005003219A0/xx unknown
- 2003-08-19 TW TW092122692A patent/TW200410946A/zh unknown
- 2003-08-19 ES ES03792388T patent/ES2295682T3/es not_active Expired - Lifetime
- 2003-08-19 EP EP03792388A patent/EP1539712B1/en not_active Expired - Lifetime
- 2003-08-19 OA OA1200500052A patent/OA12910A/en unknown
- 2003-08-19 KR KR1020057002813A patent/KR20050058367A/ko not_active Ceased
- 2003-08-19 JP JP2004530220A patent/JP4583174B2/ja not_active Expired - Fee Related
- 2003-08-19 UA UAA200501583A patent/UA83194C2/ru unknown
- 2003-08-19 BR BR0313676-0A patent/BR0313676A/pt not_active IP Right Cessation
- 2003-08-19 AU AU2003264076A patent/AU2003264076B2/en not_active Ceased
- 2003-08-19 DE DE60335151T patent/DE60335151D1/de not_active Expired - Lifetime
- 2003-08-19 DK DK03792388T patent/DK1539712T3/da active
- 2003-08-19 EA EA200700934A patent/EA012703B1/ru not_active IP Right Cessation
- 2003-08-19 DE DE60317348T patent/DE60317348T2/de not_active Expired - Lifetime
- 2003-08-19 AT AT07119063T patent/ATE489369T1/de not_active IP Right Cessation
- 2003-08-19 PT PT03792388T patent/PT1539712E/pt unknown
- 2003-08-19 MX MXPA05001960A patent/MXPA05001960A/es active IP Right Grant
- 2003-08-19 AT AT03792388T patent/ATE377591T1/de active
- 2003-08-19 NZ NZ537886A patent/NZ537886A/en unknown
- 2003-08-19 CA CA2495880A patent/CA2495880C/en not_active Expired - Fee Related
- 2003-08-19 PE PE2003000839A patent/PE20040898A1/es not_active Application Discontinuation
- 2003-08-19 SI SI200331088T patent/SI1539712T1/sl unknown
- 2003-08-19 EP EP07119063A patent/EP1878725B1/en not_active Expired - Lifetime
- 2003-08-19 EA EA200500392A patent/EA010130B1/ru not_active IP Right Cessation
- 2003-08-19 US US10/524,470 patent/US7635701B2/en not_active Expired - Fee Related
- 2003-08-19 AR ARP030102997A patent/AR041016A1/es unknown
2005
- 2005-01-27 IL IL16655205A patent/IL166552A0/xx unknown
- 2005-02-01 ZA ZA200500913A patent/ZA200500913B/xx unknown
- 2005-02-18 EC EC2005005613A patent/ECSP055613A/es unknown
- 2005-03-07 MA MA28132A patent/MA27428A1/fr unknown
- 2005-03-17 IS IS7749A patent/IS7749A/is unknown
- 2005-03-18 NO NO20051451A patent/NO20051451D0/no not_active Application Discontinuation
2007
- 2007-08-27 IL IL185549A patent/IL185549A0/en unknown
2008
- 2008-01-31 CY CY20081100115T patent/CY1107871T1/el unknown
2009
- 2009-10-21 US US12/582,861 patent/US20100041654A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2004018433A1 (en)	2004-03-04
DE60317348T2 (de)	2008-08-28
IL185549A0 (en)	2008-01-06
AU2003264076A1 (en)	2004-03-11
ECSP055613A (es)	2005-04-18
NO20051451L (no)	2005-03-18
ES2295682T3 (es)	2008-04-16
SI1539712T1 (sl)	2008-04-30
CA2495880C (en)	2010-04-27
JP4583174B2 (ja)	2010-11-17
JP2006501228A (ja)	2006-01-12
DK1539712T3 (da)	2008-03-17
ATE489369T1 (de)	2010-12-15
PL376047A1 (en)	2005-12-12
AP2005003219A0 (en)	2005-03-31
UY27939A1 (es)	2004-03-31
EP1878725A2 (en)	2008-01-16
MY137053A (en)	2008-12-31
CN1688552A (zh)	2005-10-26
CN100351239C (zh)	2007-11-28
BR0313676A (pt)	2005-06-21
OA12910A (en)	2006-10-13
IL166552A0 (en)	2006-01-15
EP1878725B1 (en)	2010-11-24
EA200700934A1 (ru)	2007-08-31
ZA200500913B (en)	2006-07-26
EP1539712A1 (en)	2005-06-15
UA83194C2 (ru)	2008-06-25
DE60335151D1 (de)	2011-01-05
NO20051451D0 (no)	2005-03-18
EA010130B1 (ru)	2008-06-30
AR041016A1 (es)	2005-04-27
PT1539712E (pt)	2008-02-08
MA27428A1 (fr)	2005-07-01
KR20050058367A (ko)	2005-06-16
PE20040898A1 (es)	2005-01-07
ATE377591T1 (de)	2007-11-15
HK1079193A1 (en)	2006-03-31
CA2495880A1 (en)	2004-03-04
EA012703B1 (ru)	2009-12-30
NZ537886A (en)	2007-05-31
EP1878725A3 (en)	2008-01-30
DE60317348D1 (de)	2007-12-20
US20100041654A1 (en)	2010-02-18
US7635701B2 (en)	2009-12-22
TW200410946A (en)	2004-07-01
AU2003264076B2 (en)	2007-09-20
CY1107871T1 (el)	2013-06-19
EP1539712B1 (en)	2007-11-07
EA200500392A1 (ru)	2005-08-25
MXPA05001960A (es)	2005-04-28
US20060293354A1 (en)	2006-12-28

Publication	Publication Date	Title
IS7749A (is)	2005-03-17	Pýrimídínafleiður og notkun þeirra sem CB2 beina
IS7881A (is)	2005-06-02	CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
IS7520A (is)	2004-11-03	Pyrimidínonefnasambönd, samsetningar og aðferðir
ATE472536T1 (de)	2010-07-15	Pyridin- und pyrimidin-derivate
IS2529B (is)	2009-07-15	Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
DK1483247T3 (da)	2009-08-17	Arylsubstituerede pyrimidiner og anvendelsen deraf
DK1572670T3 (da)	2007-12-17	5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DK1551802T3 (da)	2010-03-15	Indol-3-svovlderivater
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
ATE438628T1 (de)	2009-08-15	Pyridazinderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
IL163868A0 (en)	2005-12-18	Hermiasterlin derivatives and uses thereof
AU2003202091A8 (en)	2003-06-10	Guanidine derivatives
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DE60323721D1 (de)	2008-11-06	Verdeckter Reissverschluss
FI20022005A7 (fi)	2004-05-09	Liitoskappale
PL376897A1 (pl)	2006-01-09	Podstawione 6-(2-chlorowcofenylo) triazolopirymidyny
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
EP1481610A4 (en)	2005-07-13	PORTABLE BOOK RACK